ES 481
Alternative Names: ES-481Latest Information Update: 06 Jun 2024
Price :
$50 *
At a glance
- Originator ES Therapeutics
- Developer ES Therapeutics; ES Therapeutics Australia
- Class Antiepileptic drugs
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Epilepsy; Tremor
Most Recent Events
- 13 Apr 2024 Efficacy and adverse event data from phase II trial in Epilepsy presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
- 22 Apr 2022 ES Therapeutics withdraws a phase II trial in Epilepsy (PO, Capsule) (NCT04737174)
- 21 Nov 2021 Phase-II clinical trials in Tremor in Canada (PO) (NCT05234762)